Immunotherapy in Renal Cell Carcinoma: The Future Is Now
| العنوان: | Immunotherapy in Renal Cell Carcinoma: The Future Is Now |
|---|---|
| المؤلفون: | Laurence Crouzet, Antoine Deleuze, Frédéric Dugay, Judikaël Saout, Marc-Antoine Belaud-Rotureau, Brigitte Laguerre, Benoit Peyronnet, Karim Bensalah, Solène-Florence Kammerer-Jacquet, Gregory Verhoest, N. Rioux-Leclercq, Romain Mathieu |
| المساهمون: | Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Eugène Marquis (CRLCC), CHU Pontchaillou [Rennes], Service de Pathologie [Rennes] = Pathology [Rennes], Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Jonchère, Laurent |
| المصدر: | International Journal of Molecular Sciences International Journal of Molecular Sciences, 2020, 21 (7), pp.2532. ⟨10.3390/ijms21072532⟩ International Journal of Molecular Sciences, MDPI, 2020, 21 (7), pp.2532. ⟨10.3390/ijms21072532⟩ International Journal of Molecular Sciences, Vol 21, Iss 2532, p 2532 (2020) |
| بيانات النشر: | MDPI, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, medicine.medical_treatment, Immune checkpoint inhibitors, [SDV]Life Sciences [q-bio], Review, lcsh:Chemistry, immune checkpoint inhibitors, 0302 clinical medicine, Renal cell carcinoma, PD-1, lcsh:QH301-705.5, Spectroscopy, 0303 health sciences, Clinical Trials as Topic, biology, Treatment options, General Medicine, Kidney Neoplasms, 3. Good health, Computer Science Applications, [SDV] Life Sciences [q-bio], emerging drugs, 030220 oncology & carcinogenesis, Urologic cancer, Immunotherapy, PD-L1, medicine.medical_specialty, Poor prognosis, renal cell carcinoma, Catalysis, Unmet needs, Inorganic Chemistry, 03 medical and health sciences, Internal medicine, ongoing trials, medicine, Animals, Humans, Physical and Theoretical Chemistry, Molecular Biology, Carcinoma, Renal Cell, 030304 developmental biology, business.industry, Organic Chemistry, biomarkers, medicine.disease, lcsh:Biology (General), lcsh:QD1-999, biology.protein, business |
| الوصف: | International audience; Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare with a high rate of resistance. New strategies are emerging to improve the efficacy and the emerging drugs are under evaluation in ongoing trials. With the different treatment options, there is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients. Owing to the limitations of programmed death-ligand 1 (PD-L1), the most studied immunohistochemistry biomarkers, and of the tumor mutational burden, the identification of more reliable markers is an unmet need. New technologies could help in this purpose. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1422-0067 1661-6596 |
| DOI: | 10.3390/ijms21072532⟩ |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e8677ba3878705c1d045075b863500 http://europepmc.org/articles/PMC7177761 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....68e8677ba3878705c1d045075b863500 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14220067 16616596 |
|---|---|
| DOI: | 10.3390/ijms21072532⟩ |